Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 10, 2009
Mon, February 9, 2009 AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2008 Financial Results
WEST CHESTER, Ohio--([ BUSINESS WIRE ])--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the fourth quarter and year ended December 31, 2008 on Thursday, February 19, 2009.
AtriCure will host a conference call at 10:00 a.m. Eastern Time on Thursday, February 19, 2009 to discuss its fourth quarter and full year 2008 financial results. A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at [ www.atricure.com ].
Pre-registration is available for this call at the following URL:
[ https://www.theconferencingservice.com/prereg/key.process?key=PBEURJXKW ]
Pre-registering is recommended and only takes a few moments. You may pre-register at any time, including up to and after the call start time. Alternatively, if you prefer being placed into the call by an operator, please call 888-679-8018 for domestic callers and 617-213-4845 for international callers at least 15 minutes prior to the call start time and use reservation number 85153861.
The web cast will remain available on AtriCure's web site through March 21, 2009. A telephonic replay of the call will also be available until March 19, 2009. The replay dial-in numbers are 888-286-8010 for domestic callers and 617-801-6888 for international callers. Please use reservation code 74400223.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator® bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator® system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator® system, including its Isolator SynergyTM ablation clamps, and AtriCure's multifunctional pen and CoolrailTM linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use.
